Prostemics Co. Ltd (203690) - Cash Flow Conversion Efficiency

Latest as of March 2026: -0.036x

Based on the latest financial reports, Prostemics Co. Ltd (203690) has a cash flow conversion efficiency ratio of -0.036x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-900.50 Million ≈ $-610.25K USD) by net assets (₩24.87 Billion ≈ $16.85 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Prostemics Co. Ltd to measure how much of total assets are equity-financed.

Prostemics Co. Ltd - Cash Flow Conversion Efficiency Trend (2015–2025)

This chart illustrates how Prostemics Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Prostemics Co. Ltd (203690) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.

Prostemics Co. Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Prostemics Co. Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
BT Wealth Industries Public Company Limited BK:BTW	-0.152x
KINGS ENTERTAINMENT GROUP F:L12	N/A
Astron Paper & Board Mill Limited NSE:ASTRON	0.079x
Filament Health Corp NEO:FH	-0.228x
MJ Gleeson plc LSE:GLE	0.070x
ETRUSCUS RESOURCES CORP. F:ERR	-0.014x
Nexera Energy Inc V:NGY	-0.007x
Rainbow Rare Earths Limited LSE:RBW	-0.245x

Annual Cash Flow Conversion Efficiency for Prostemics Co. Ltd (2015–2025)

The table below shows the annual cash flow conversion efficiency of Prostemics Co. Ltd from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see 203690 stock market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	₩25.96 Billion ≈ $17.59 Million	₩-10.11 Billion ≈ $-6.85 Million	-0.390x	-426.57%
2024-12-31	₩25.94 Billion ≈ $17.58 Million	₩-1.92 Billion ≈ $-1.30 Million	-0.074x	+67.06%
2023-12-31	₩30.43 Billion ≈ $20.62 Million	₩-6.84 Billion ≈ $-4.63 Million	-0.225x	+53.77%
2022-12-31	₩9.83 Billion ≈ $6.66 Million	₩-4.78 Billion ≈ $-3.24 Million	-0.486x	-325.35%
2021-12-31	₩13.93 Billion ≈ $9.44 Million	₩3.00 Billion ≈ $2.04 Million	0.216x	+199.11%
2020-12-31	₩21.47 Billion ≈ $14.55 Million	₩-4.67 Billion ≈ $-3.17 Million	-0.218x	-1349.04%
2019-12-31	₩28.35 Billion ≈ $19.21 Million	₩-425.74 Million ≈ $-288.52K	-0.015x	+79.48%
2018-12-31	₩31.89 Billion ≈ $21.61 Million	₩-2.33 Billion ≈ $-1.58 Million	-0.073x	+13.86%
2017-12-31	₩39.16 Billion ≈ $26.54 Million	₩-3.33 Billion ≈ $-2.25 Million	-0.085x	-164.99%
2016-12-31	₩44.86 Billion ≈ $30.40 Million	₩5.86 Billion ≈ $3.97 Million	0.131x	-17.60%
2015-12-31	₩39.38 Billion ≈ $26.69 Million	₩6.25 Billion ≈ $4.23 Million	0.159x	--

About Prostemics Co. Ltd

KQ:203690 Korea Biotechnology

Market Cap

$1.88 Million

₩2.78 Billion KRW

Market Cap Rank

#30084 Global

#2100 in Korea

Share Price

₩139.00

Change (1 day)

+0.00%

52-Week Range

₩139.00 - ₩139.00

All Time High

₩77250.00